Alcon (ALC) Receives a Buy from Needham

Needham analyst David Saxon reiterated a Buy rating on Alcon (ALCResearch Report) today and set a price target of $87.00. The company’s shares closed last Monday at $78.07.

According to, Saxon ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.0% and a 33.3% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Irhythm Technologies, Alphatec Holdings, and Staar Surgical.

Currently, the analyst consensus on Alcon is a Moderate Buy with an average price target of $84.56.

See the top stocks recommended by analysts >>

The company has a one-year high of $88.78 and a one-year low of $63.92. Currently, Alcon has an average volume of 852.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alcon Inc. is a medical company which is specialized in eye care products. The company develops, manufactures, distributes, and sells technologies and devices for cataract, retinal, refractive surgery, as well as contact lenses and lens care products.

Read More on ALC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More